DI Life Science Webinar - Exploring China’s Healthcare Market – Trends, Opportunities, and Challenges

Hear about the rapidly evolving Chinese healthcare market, the real experiences of Coloplast and Novo Holdings, the fast-track policies and opportunities at Hainan Boao Lecheng International Medical Zone, and how you can benefit from a step-by-step market entry model.

As a result of major demographic changes such as a rapidly aging population that is leading to a growing number of chronic diseases, China is investing massively in modern hospitals, innovative medical products, and new treatment methods to satisfy the rising demand for high-quality healthcare services.

This development represents a major and fast-growing business opportunity for Danish life science companies with innovative medical products that wish to tap into the world’s 2^nd largest healthcare market.

At the webinar, Coloplast will present how they address the Healthy China 2030 Plan and Common Prosperity Agenda while Novo Holdings will look at the business opportunities and challenges in the Chinese healthcare market and how this impacts their investment strategy.

To explore the market opportunities in China further, the Danish Life Science Cluster (DLSC), Nordic Life Science Partners ApS (NLSP), and Innovation Center Denmark Shanghai have established a Partnership.

The aim is to give Danish companies a more safe, efficient, and easier access to China’s healthcare market by taking advantage of the fast-track policies and opportunities at the “Hainan Boao Lecheng International Medical Tourism Pilot Zone” (HBL) that serves as a stepping-stone to Mainland China. In October 2023, DLSC and NLSP signed a strategic cooperation agreement with the HBL Administration.

HBL offers fast-track approvals for innovative medical devices, drugs and rehabilitation equipment that are not registered in China but approved overseas with a CE mark or FDA license which gives direct access to the currently 25 private and public hospitals at HBL in which some are branches of leading hospitals in Mainland China.

HBL is also the only place in China where it is possible to conduct Real-World Data studies with the fast-track approvals that can supplement the application for the NMPA registration and accelerate the approval process to sell in all of Mainland China which has already attracted some Danish companies.

Who should participate?
Medical device, pharmaceutical and rehabilitation companies with a CE-mark or FDA approval that are interested in entering or expanding their activities in the Chinese healthcare market and seek practical advice and support from experienced China experts who can guide your company through the entire market entry process with HBL as a stepping stone to the rest of Mainland China.

Program (CET / +6 hours, CST)

N.B.: Once you have signed up for the webinar, you will receive a link to the webinar a few days in advance.